retatrutide triple agonist glp-1 gip glucagon phase 2 obesity 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide Phase 3: 28.7% Weight

Chen J, Qiu Y, Zhang S, Gao Y

Int J Diabetes Dev Ctries 43 , 856874 (2023)

(2018) Prostaglandin E1 plus methylcobalamin combination therapy versus prostaglandin E1 monotherapy for patients with diabetic peripheral neuropathy: A meta-analysis of randomized controlled trials

Enhanced Energy Production: Boosts energy levels by facilitating the transport of fatty acids into the mitochondria, where they are converted into ATP, the body's primary energy source

This means Ozempic is designed to imitate natural GLP-1 hormone activity, offering similar benefits but with longer-lasting effects

A 12-month commitment is required, but users praise the community approach